Navigation Links
Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
Date:6/8/2012

SOUTH PLAINFIELD, N.J., June 8, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. today announced the results from a Phase 3 study of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). The results demonstrated positive trends in lung function as measured by FEV1 (forced expiratory volume in one second) and in the secondary outcome measure, rate of pulmonary exacerbations. Results also showed a substantial ataluren treatment effect in FEV1 and exacerbation rate in the pre-specified subpopulation of patients not receiving chronic inhaled antibiotics, representing approximately one half of the study population. These data were presented at the European Cystic Fibrosis Society Conference in Dublin, Ireland.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO )

"The data from this trial are promising. Ataluren has the potential to provide benefit to patients with nonsense mutation cystic fibrosis, who currently have few treatment options. Nonsense mutations do not produce any functional CFTR protein and therefore generally result in a more severe form of cystic fibrosis," stated Michael Konstan, M.D., a principal investigator at University Hospitals Rainbow Babies and Children's Hospital in Cleveland, Ohio. "Correcting a nonsense mutation in the cystic fibrosis transmembrane conductance regulator gene is a big challenge. Over 48 weeks, the decrease in FEV1 in ataluren was 50% less than the decrease on placebo, which is a substantial difference. It is also very important to note that the FEV1 and exacerbations tracked closely." 

This Phase 3 study, which was conducted across 11 countries, was a double-blind, placebo-controlled study comparing ataluren (n=116) to placebo (n=116) in nmCF patients. The primary endpoint, the relative change from baseline in %-predicted FEV1 at 48 weeks, showed a positive trend favoring atalur
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
2. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
3. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
4. Sorrento Therapeutics Awarded Third Phase I STTR Grant
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
7. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
8. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
9. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
10. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
11. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014 In the latest call ... sexual dysfunction, more than 60 doctors and leading medical ... letter questioning the Food and Drug Administration,s (FDA) decision ... form of male sexual dysfunction compared with ZERO for ... to act for women by approving the first-ever drug ...
(Date:8/1/2014)... , Ill. and PALO ALTO, Calif. ... Fibrosis Research, Inc. (CFRI) today announced a partnership to ... fibrosis (CF) community through the CFChef Shares program. CFChef ... 2014, as part of AbbVie,s CFChef program – an ... encourage patients to maintain a healthy diet by submitting ...
(Date:8/1/2014)... Calif. , Aug. 1, 2014  Isis Pharmaceuticals, ... initiation of a pivotal Phase 3 study evaluating ISIS-SMN ... the most common genetic cause of infant mortality. Isis ... within the next few weeks, at which time Isis ... development partner, Biogen Idec. The Phase 3 study, ENDEAR, ...
Breaking Medicine Technology:60+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5
... research sponsored by CVS Caremark examined the effects ... on medication adherence when the warnings are not ... that immediately following a high-profile FDA communication questioning ... level of patients who stopped filling their prescription ...
... 23 2012  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... EAS 2012When:Friday, June 1st at 12:00 p.m. ET / ... our Web site listed above. If you are unable ... the webcast will be available for a limited time ...
Cached Medicine Technology:CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety 2CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety 3
(Date:8/1/2014)... benefits of a cancer diagnosis may improve health outcomes ... conducted by a researcher at the University of Houston ... writing intervention is the writing instruction. Otherwise, writing is ... a journal can be therapeutic, but oftentimes we don,t ... or not," said Qian Lu, assistant professor and director ...
(Date:8/1/2014)... 01, 2014 Hot off the presses after ... category of the World’s Best Awards by Travel + ... celebration of National Relaxation Day (technically August 15). , ... MAJOR experts to help guests celebrate relaxation throughout the month ... for health and wellness to carve out time to relax ...
(Date:8/1/2014)... Mozes HealthDay Reporter FRIDAY, ... serve as a time-honored destination for a good cut and ... might also be the spot to tackle an often overlooked ... a novel partnership, the U.S. Centers for Disease Control and ... enlisted the help of barbershop staff to both discuss and ...
(Date:8/1/2014)... August 01, 2014 For years, proponents ... A recent study conducted by the Ohio ... too far behind in terms of their health and ... know what’s best for their baby. So does this ... Dr. Steven Shapiro , chair of Pediatrics at ...
(Date:8/1/2014)... GlobalDatas new report, "United ... provides key market data on the United ... value, in millions of US dollars, volume ... dollars) within market segments - Electrosurgical RF ... Plasma Coagulation Generators. , To view the ...
Breaking Medicine News(10 mins):Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3
... and Drug Administration (FDA) has approved the NeuRx Diaphragm ... dependent on ventilators for breathing. The light-weight, battery-powered ... naturally, while eliminating the need for a power source ... was developed over the course of 20 years through ...
... safety program launched more than two years ago ... significantly improved communication between caregivers and patients and ... the program has found. , Children,s Hospital became ... with the Josie King Foundation to launch a ...
... proVision(TM) Now Manages Over 150,000 Identities, ANDOVER, ... the past six months, seven healthcare organizations have ... processes that eliminate the challenges of manual user ... (Nashville, TN) -- Baptist Health System (Birmingham, ...
... inspiring stories of Minnesotans who ... struggled to ... personally struggled to go smoke-free are sharing their,stories, from the time ... Their inspiring stories will be showcased in,ClearWay Minnesota,s traveling photo essay ...
... born by Caesarean section have a 50 % increased risk ... sections increase the risk even further. This is shown in ... registered at the Medical Birth Registry at the Norwegian Institute ... was to investigate the possible link between being born by ...
... CHAPEL HILL Psychosocial influences such as stress, depression ... studies involving people infected with HIV, yet they are ... individuals and the spread of AIDS, according to a ... , Now, a comprehensive update on those influences in ...
Cached Medicine News:Health News:FDA approves NeuRx diaphragm pacing system for use in spinal cord- injured patients 2Health News:Study finds Children's Hospital patient safety program improves caregiver/family communications 2Health News:Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning 2Health News:Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning 3Health News:In Smoke-Free Minnesota, Five Former Smokers Share Their Struggles With Fighting Addiction 2Health News:In Smoke-Free Minnesota, Five Former Smokers Share Their Struggles With Fighting Addiction 3Health News:In Smoke-Free Minnesota, Five Former Smokers Share Their Struggles With Fighting Addiction 4Health News:Caesarean sections associated with risk of asthma 2Health News:Psychosocial issues affect HIV/AIDS treatment outcomes: UNC researcher 2Health News:Psychosocial issues affect HIV/AIDS treatment outcomes: UNC researcher 3
... Parathyroid hormone (PTH) is synthesized ... secreted in response to decreased extracellular ... enhancing bone resorption and decreasing calcium ... into the circulation, intact PTH is ...
... the adrenal cortex and, to a lesser ... a precursor in testosterone and estrogen synthesis, ... at ~10% that of testosterone [1]. However, ... women, DHEA is an important androgen as ...
... steroid, is one of the most potent ... testosterone is secreted primarily by the testes ... peripheral conversion of androstenedione [2]. In adult ... 50% of serum testosterone is derived from ...
... Thyroxine (T4) is the primary active ... the thyroid gland [1]. T4 is synthesized ... iodide trapping by the follicular cells, (ii) ... substrate leading to formation of 3-monoiodotyrosine and ...
Medicine Products: